Apple, Alphabet, Dexcom.....

[peppy]

Aug 10, 2019 11:32:22 GMT -5 goyocafe said:

Aug 10, 2019 8:49:24 GMT -5 goyocafe said:

It’s a curious photo to me to see OneDrop included with Dexcom except for one thing; the expanded coaching service and accompanying database of customers that Dachi’s company has amassed over the past few years. I can see a Google type company taking an agnostic approach to device and drug integration with a more holistic objective of providing a best in class connected health care service. That said, they would ultimately choose drugs and devices that offer the best outcomes for its patients.

I think this photo actually originated from an Instagram user named @mjaimerd2be and is given credit for it by @dexcomwarriors. @dexcom looks like a locked or unused account. Not sure who is behind @dexcomwarriors. There are a number of photos on @mjaimerd2be's page with references to Afrezza. Worth a look. www.instagram.com/mjaimerd2be/

Time frames are everything. 



www.instagram.com/mjaimerd2be/

[shawnonafrezza]

Aug 10, 2019 6:48:38 GMT -5 akemp3000 said:

Aug 9, 2019 23:27:16 GMT -5 sellhighdrinklow said:

I say Afrezza is next for the grand slam.

www.cnbc.com/video/2019/08/02/why-apple-and-alphabet-are-partnering-with-diabetes-company-dexcom.html

It may not be big pharma that's been shorting MNKD, maybe it's those listed above.

Makes 100% sense to me. Are they that shrewd?

I say yes.

Grand slam pending.

Really great and interesting video. Dexcom's G7 in early 2020 will be another big step forward. The only thing missing is a drug that actually works in tandem with a CGM to greatly improve diabetics time-in-range...hmmm

Current trials on closed loops beg to differ.




Aug 10, 2019 6:56:41 GMT -7 bioexec25 said:

Interesting comments about the lag time and algos used in the latest software.

www.liebertpub.com/doi/full/10.1089/dia.2018.0364

This lag doesn't go away with Afrezza. Now you have the same lag + the lag for human to act.

[akemp3000]

A trial of 4 males and 13 females with T1 diabetes on pumps isn't an equitable comparison or representative of a drug that can actually work in tandem with a CGM for most diabetics.

[apidistra]

The last thing I would want is the interference of Google, if that is what it being claimed here. Golly, I hope not. That company has no business plan, it's all over the map technologically, has more failures and money losing propositions than commercial successes and lives on digital ad revenue. That would be a total NO to me.

[shawnonafrezza]

Aug 11, 2019 10:41:01 GMT -5 akemp3000 said:

A trial of 4 males and 13 females with T1 diabetes on pumps isn't an equitable comparison or representative of a drug that can actually work in tandem with a CGM for most diabetics.

What? You do realize the study you're arguing against was saying the pumps **weren't** good, right? And that study was about CGM lag, not insulin? And and that you're making a claim that there is no study backing for which is why Mannkind is in it's current situation?